Novo Nordisk reports positive results for high-dose Wegovy …
2 days ago · Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks.
Novo Nordisk’s high-dose Wegovy increases weight loss and …
3 days ago · Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...
Novo Nordisk Says Higher-Dose Wegovy Achieves Greater
6 days ago · Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according ...
Novo Nordisk Links High-Dose Wegovy to Increased Weight …
6 days ago · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy. ... The reveal of the 7.2 mg data coincided with the news that the Centers for Medicare and ...
Novo shares high-dose Wegovy results; Amgen, AstraZeneca …
6 days ago · A high-dose form of Novo Nordisk’s obesity drug Wegovy, together with lifestyle intervention, led to greater weight loss over 72 weeks than the current approved dose, according to results from a Phase 3b study. Study participants given a 7.2 milligram dose of Wegovy lost, on average, 20.7% of their body weight, versus 17.5% among those on a 2 ...
Novo Suffers Wegovy Trial Setback as US Plans to Cut Price
6 days ago · Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early ...
What the results of Wegovy’s longest clinical trial yet show about ...
May 13, 2024 · More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a...
News Details - Novo Nordisk
Mar 8, 2024 · "We are very pleased that Wegovy ® is now approved in the US as the first therapy to help people manage their weight and reduce cardiovascular risks," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk.
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …
News details - Novo Nordisk
PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along ...